Literature DB >> 22047791

Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Isaac Levy1, Anelia Horvath, Monalisa Azevedo, Rodrigo Bertollo de Alexandre, Constantine A Stratakis.   

Abstract

Phosphodiesterases (PDEs) are enzymes that regulate the intracellular levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate, and, consequently, exhibit a central role in multiple cellular functions. The pharmacological exploitation of the ability of PDEs to regulate specific pathways has led to the discovery of drugs with selective action against specific PDE isoforms. Considerable attention has been given to the development of selective PDE inhibitors, especially after the therapeutic success of PDE5 inhibitors in the treatment of erectile dysfunction. Several associations between PDE genes and genetic diseases have been described, and more recently PDE11A and PDE8B have been implicated in predisposition to tumor formation. This review focuses on the possible function of PDEs in a variety of tumors, primarily in endocrine glands, both in tumor predisposition and as potential therapeutic targets.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22047791      PMCID: PMC4727450          DOI: 10.1016/j.coph.2011.10.003

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  107 in total

Review 1.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

Authors:  Celine Mehats; Carsten B Andersen; Marcello Filopanti; S L Catherine Jin; Marco Conti
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

2.  VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors.

Authors:  Laure Favot; Thérèse Keravis; Vincent Holl; Alain Le Bec; Claire Lugnier
Journal:  Thromb Haemost       Date:  2003-08       Impact factor: 5.249

Review 3.  Phototransduction: crystal clear.

Authors:  Kevin D Ridge; Najmoutin G Abdulaev; Marcelo Sousa; Krzysztof Palczewski
Journal:  Trends Biochem Sci       Date:  2003-09       Impact factor: 13.807

4.  Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.

Authors:  Rossella Libé; Anelia Horvath; Delphine Vezzosi; Amato Fratticci; Joel Coste; Karine Perlemoine; Bruno Ragazzon; Marine Guillaud-Bataille; Lionel Groussin; Eric Clauser; Marie-Laure Raffin-Sanson; Jennifer Siegel; Jason Moran; Limor Drori-Herishanu; Fabio Rueda Faucz; Maya Lodish; Maria Nesterova; Xavier Bertagna; Jerome Bertherat; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2010-11-03       Impact factor: 5.958

5.  Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells.

Authors:  Z Zhao; C E Francis; G Welch; J Loscalzo; K Ravid
Journal:  Biochim Biophys Acta       Date:  1997-11-27

Review 6.  Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3).

Authors:  E Degerman; P Belfrage; V C Manganiello
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

7.  PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis.

Authors:  Vasiliki Koika; Zongmin Zhou; Ioannis Vasileiadis; Charis Roussos; Federica Finetti; Martina Monti; Lucia Morbidelli; Andreas Papapetropoulos
Journal:  Vascul Pharmacol       Date:  2010-09-08       Impact factor: 5.773

8.  3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues.

Authors:  K Loughney; J Taylor; V A Florio
Journal:  Int J Impot Res       Date:  2005 Jul-Aug       Impact factor: 2.896

9.  Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.

Authors:  Fabio Rueda Faucz; Anelia Horvath; Anya Rothenbuhler; Madson Q Almeida; Rossella Libé; Marie-Laure Raffin-Sanson; Jerome Bertherat; Dirce Maria Carraro; Fernando Augusto Soares; Gustavo de Campos Molina; Antonio H Campos; Rodrigo B Alexandre; Marcelo Luiz Bendhack; Maria Nesterova; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2010-09-29       Impact factor: 5.958

10.  Phosphodiesterase 11 (PDE11): is it a player in human testicular function?

Authors:  S H Francis
Journal:  Int J Impot Res       Date:  2005 Sep-Oct       Impact factor: 2.896

View more
  20 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

2.  Genetic variants in the calcium signaling pathway genes are associated with cutaneous melanoma-specific survival.

Authors:  Xiaomeng Wang; Hongliang Liu; Yinghui Xu; Jichun Xie; Dakai Zhu; Christopher I Amos; Shenying Fang; Jeffrey E Lee; Xin Li; Hongmei Nan; Yanqiu Song; Qingyi Wei
Journal:  Carcinogenesis       Date:  2019-04-29       Impact factor: 4.944

Review 3.  Phosphodiesterases and adrenal Cushing in mice and humans.

Authors:  E Szarek; C A Stratakis
Journal:  Horm Metab Res       Date:  2014-09-18       Impact factor: 2.936

4.  Adrenoceptor modulators and cancer progression.

Authors:  Kazuyoshi Hirota
Journal:  J Anesth       Date:  2016-04-06       Impact factor: 2.078

Review 5.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

Review 6.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

7.  Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay.

Authors:  L-C L Tsai; G C-K Chan; S N Nangle; M Shimizu-Albergine; G L Jones; D R Storm; J A Beavo; L S Zweifel
Journal:  Genes Brain Behav       Date:  2012-09-04       Impact factor: 3.449

Review 8.  The diverse roles of calcium-binding protein regucalcin in cell biology: from tissue expression and signalling to disease.

Authors:  Ricardo Marques; Cláudio J Maia; Cátia Vaz; Sara Correia; Sílvia Socorro
Journal:  Cell Mol Life Sci       Date:  2013-03-22       Impact factor: 9.261

9.  Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors - Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP.

Authors:  Anders L Selli; Adrina K Kuzmiszyn; Natalia Smaglyukova; Timofei V Kondratiev; Ole-Martin Fuskevåg; Roy A Lyså; Aina W Ravna; Torkjel Tveita; Georg Sager; Erik S Dietrichs
Journal:  Front Physiol       Date:  2021-07-30       Impact factor: 4.566

Review 10.  Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.

Authors:  Ariana A Entezari; Adam E Snook; Scott A Waldman
Journal:  Expert Opin Ther Targets       Date:  2021-06-15       Impact factor: 6.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.